Inovio Biomedical H5N1 Avian Influenza DNA Vaccine Receives Korean Approval to Begin Clinical Trials

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. (Korean Stock Exchange: 011000) has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza. Inovio is co-developing VGX-3400 with Korea-based VGX International. The 30-patient three-

For more information, please visit
http://www.businesswire.com/news/home/20100302005791/en

You need to login to post comments.

Feed last updated 1969/12/31 @7:00 PM

0 COMMENTS:

VOCAPIA and SYSTRAN demonstrate an automated speech translation solution at EUROSATORY 2016 - GlobeNewswire (press release) views: 1527

Instagram is adding automatic in-app text translation - The Verge views: 1521

Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1505

F.A.Q. | Terms and conditions